Embolotherapy of Cholangiocarcinoma, 2016 updates - GEST 2018

Embolotherapy of Cholangiocarcinoma, 2016 updates - GEST 2018

Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Cent...

2MB Sizes 0 Downloads 0 Views

Recommend Documents

2016 Topps Updates Checklist
Robin Yount. Milwaukee Brewers™. 3000H-12. Tony Gwynn. San Diego Padres™. 3000H-13. Ichiro. Miami Marlins®. 3000H-1

erdgeschoss obergeschoss - GEST
SSE. Treppenhaus zum Sitzungssaal gr. Parkhaus zugänglich von der Humboldstr. zur. U-Bahn-Station. Mundsburg ca. 5-10.

Genetic Factors in the Pathogenesis of Cholangiocarcinoma
e Catherine Williamson b Shahid A. Khan a a Department of Hepatology and Gastroenterology, b Institute of Reproductive a

Gest - CV - March 2017 - Justin Gest - George Mason University
Oxford University Press (North America and Europe). Featured in The New York Times, The Washington Post, The Guardian, F

2016-2018 catalog - UTHealth
Associate Professor. Moises Nevah Rubin, MD. Assistant Professor. Jen Jung Pan, MD, ...... Saba Memon, MD. Clinical Assi

2016-2018 GATEWAY PROGRAM MEMORANDUM OF - PAARI
Between the City of Ashland Police Department and OnTrack Inc. 6. If to OnTrack Inc: If to the City of Ashland Police De

2016 ARDMORE DEVELOPMENT AUTHORITY 2018 2016 2017
EMAIL [email protected] STEVE JORDAN. JORDAN INSURANCE GROUP. 616 Sunset Drive. PH 465-9100. EMAIL [email protected]

Omni Updates
AXA Equitable Life Insurance Company. GWN/Employee Deposit Acct. Lincoln Investment Planning. Midland National Life Insu

Alumni Updates
Kellie (Reali) Thompson ('12) got married on July 14, 2012, to Danny Thompson (a loyal Oakland. A's fan!), in a beautifu

Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology

Long Island Jewish Medical Center

GEST 2016

Igor Lobko, M.D. • No relevant financial relationship reported

Cholangiocarcinoma Embolization • Recent Literature • Ongoing Studies • When is Embolization of Cholangiocarcinoma appropriate? Patient Selection Prognostic Factors Does Size Matter? Tumor Enhancement – What does it mean? • Cholangicarcinoma IR Therapies Algorithm

Cholangiocarcinoma • Primary malignant neoplasm of the hepatobiliary system arising from the biliary ducts epithelia • Second most common primary malignancy of the liver • 2000-3000 new cases a year in USA, 1.67/100000 • More common in South East Asia: China 0.97-7.5, Korea 7.1-8.75, Thailand 5.7-85/100000 • Usually diagnosed at advanced stage, have a poor prognosis

Literature Review

Trans arterial Therapies

Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. • 20 articles, 657 patients • Median OS: HAI – 22.8 months TARE – 13.9 months TACE – 12.4 months DEB-TACE – 12.3 months • Toxicity: HAI - Highest

Response Rate: 56.9% 27.4% 17.3%

Boehm LM et all, J Surg Oncol. 2015 Feb

Trans-arterial embolization therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review • 20 studies eligible for review between 2000-2013 ( 929 patients ) • 4 studies with more then 50 patients • 12 studies retrospective • No Randomized Controlled Trials • Radiological Response: complete – 10%, partial – 22% • MOS: TARE - 12.5 months; TACE – 13 months • 1 Year Survival TARE – 54.5% ( 40-61%); TACE – 53% ( 38-78%) • Negative Predictive Factors: TARE - Large Tumor Burden, Multiplicity, PS > 2 TACE - Hypovascularity, Extrahepatic Disease Linda Yang et all, Gastrointest Oncol. 2015 Oct

Intra-arterial therapy for advanced intrahepatic Cholangiocarcinoma: a multi-institutional analysis • Retrospective review 198 patients treated in 4 major centers • Compered cTACE, DEB, TAE, TARE Response: Complete or partial – 25.5% Stable disease – 61.5% Progression – 13% Medial OS 13.2 months and did not differ between IAT Similar Treatment Related Toxicities

87%

Hyder O, Ann Surg Oncol. 2013 Nov

Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysis • • • • •

12 Studies, 298 patients: 7 prospective and 5 retrospective studies No randomized studies Median OS 15.5 months Radiological Tumor Response: Partial – 28% Stable – 54%

82%

7 patients down staged to surgery D.P. Al-Adra et all, Eur J Surg Oncol. 2015 Jan

Radioembolization improves survival in intrahepatic cholangiocarcinoma: a SEER-Medicare population study • Retrospective • 585 patients: Chemotherapy 513 – 88% Chemotherapy + TARE 72 - 12% • Median Overall Survival: Chemotherapy 811 days Chemotherapy + TARE 1043 days • Combination therapy of ICC with chemotherapy and radioembolization results in a median 7.6 months of greater survival than chemotherapy alone.

Hyun S. Kim, Minzhi Xing, SIR 2016 Annual Meeting

Yttrium-90 radioembolization for unresectable combined hepatocellular-cholangiocarcinoma • • • •

Retrospective SIR Spheres 5 patients and Theraspheres 6 patients 11 patients Radiographic Response: Partial – 6 Stable – 4 • Median OS: From 1st TARE – 9.4 months From Initial Diagnosis – 18 months • Only Grade 1-2 toxicities observed

John D Louie, Daniel Sze, David S. Wang, SIR 2016 Annual Meeting

Summary of Published Data Good News • Embolotherapies for Cholangiocarcinoma Improve Survival • Relatively Low Toxicities with Acceptable Safety Profile • Similar results between different types of embolization Bad News • Low power studies due to small and heterogeneous samples • Most studies based on retrospective data analysis • No Randomized Trials

Current Studies Investigating Embolotherapies for Cholangiocarcinoma Treatment

• • • • •

6 - Ongoing Prospective Studies 2 – Dose Escalation Studies 2 - Safety and Feasibility 1 - International Cholangiocarcinoma Registry 2 - Randomized Trials

ClinicalTrials.gov

Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases, USA • • • • • •

Prospective Dose Escalation Study Theraspheres Started March 2009, enrollment completed Estimated Study Completion Date December 2017 30 Patients Primary Outcome Measures: Maximal tolerated dose of yttrium Y 90 Toxicity Time to tumor progression

90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma USA • Prospective Dose Escalation Study • SIR Spheres • Start Date July 2015 • Estimated Completion Date August 2018 • 20 patients • Primary Outcome Measure: Presence or absence of a dose limiting toxicity (DLT) of 90Y TARE in combination with gemcitabine and cisplatin

International Registry on Cholangiocarcinoma Treatment (CHOLANGIO), Italy • • • • • •

Prospective Study DEB TACE with Doxorubicin Target number of patients 40 Started July 2013 Estimated Completion date August 2016 Primary Outcome Measures: Tumor response Overall Survival • Secondary Outcome Measures: Number adverse events Quality of life

Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma, France • Prospective Safety/Efficacy Study • Theraspheres • Started September 2013 • Estimated Completion Date April 2018 • 41 Patient • Primary Outcome Measure: Radiological response rate to the treatment with the association of chemotherapy and radioembolization 3 months after TARE.

Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolization (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). Germany • • • • • •

Randomized SIR Spheres Started February 2011 Estimated Completion Date October 2016 24 Patients Primary Outcome Measures: Progression-free Survival (PFS} • Secondary Outcome Measures: Overall Survival (OS) Time to Progression (TTP)

Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin (DELTIC), USA • • • • • •

Randomized DEB TACE with Irinotecan Started July 2012 Estimated Completion Date July 2016 48 Patients Primary Outcome Measures: Tumor response according to m-RECIST Criteria • Secondary Outcome Measures: Hepatic Progression Free Survival

Future Research • Prospective studies with pre-determined and standardized data assessment. • Randomized controlled trials to assess efficacy of trans-arterial therapies in comparison with available systemic chemotherapies • Randomized controlled studies comparing different embolization therapies. • Studies focused on determining the appropriateness of each specific embolization therapy • Pre treatment imaging as a tool for choosing the specific embolization therapy. • Post treatment imaging in evaluation of the efficacy of different therapies

When is cholangiocarcinoma embolization appropriate?

• Patient Selection

• “To Be or Not to Be” OR

Failure vs Success - Does Size Matter? - Can preprocedure imaging predict the outcome? - Can favorable IR therapy be chosen prospectively?

Prognostic Factors for ICC Survival • R0 Resection: Achieved – 63% 5 Year Survival – 40-63% Local Recurrence – 62% • Lympho-Vascular Invasion • Intrahepatic Invasion • Metastases: 50-75% • Lymph Nodes Metastases: 30-50% of all patient, 25% tumor < 3cm • Multifocal Tumors

Patient Selection • No Other Local Therapies Possible: Poor Surgical Candidates Multiple Bilobar Masses Gross Vascular Invasion Unfavorable Location for Ablation Large Size: Too Big for Ablation or when Surgical Resection would live insufficient amount of functioning liver • Metastatic disease

Correlation between Tumor Size and Aggressive Futures • 443 Patients Surgical Resections for ICC • Perineural Invasion and Regional Lymph Node Metastases are independent risks for microvascular invasion in tumors > 5cm < 3cm

3-5cm

5-7cm

7-15cm

> 15cm

Microscopic Vascular Invasion

3.6%

24.7%

38.3%

32.9%

55.6%

High Tumor Grade

9.7%

19.8%

24.2%

21.1%

31.6%

Spolverato G, Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2014 Jul

Correlation between Tumor Size and Aggressive Futures

The incidence of multiple tumors, vascular invasion, and poorly undifferentiated tumors increased with tumor size (all P < .005)

Dario Ribero, MD, Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma. A Multi-institutional Analysis of 434 Patients. Arch Surg. 2012

Tumor Size and Possibility of Curative Resection 1

• Curative Resection/5 year Survival – 10% • The 5-year survival rate of 15 patients who had ICC measuring ≤2 cm in greatest dimension without lymph node metastasis or vascular invasion was 100% 2

1.

Spolverato G Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer. 2015 Nov 15

2.

Sakamoto Y, Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer. 2015 Oct 2

Ablation vs Embolization for Treatment of Cholangiocarcinoma Using Size Criteria • Ablations should be reserved for favorably located tumors < 3 cm, may be even < 2 cm. • Tumors > 3 cm should be treated with Embolotherapies. • Even for small tumors, 2-3cm, ablations combined with embolization may improve outcomes.

Tumor Enhancement as Prognostic Factor in Therapy Selection • 42 patients undergone hepatectomy • Microvascular Density (MVD) compared with tumor enhancement on CT: 24 < 16HU > 18. Low Attenuation Hypo-group-24

Higher Attenuation Hyper-group-18

Size <5/>5cm

7/17

14/4

Histologic Differentiation Well/Moderately/Poorly

2/15/7

8/6/4

2 years tumor recurrence

14

4

Survival: 1-3-5 year

49 – 17 – 17%

78-69-69%

Nanashima A, Intrahepatic cholangiocarcinoma: relationship between tumor imaging enhancement by measuring attenuation and clinicopathologic characteristics. Abdom Imaging. 2013 Aug,

Metastatic Disease Multiple Tumors High Grade Gross Vascular Invasion

Cholangiocarcinoma < 2cm

2-3 cm

> 3cm

Ablation

Ablation +/- Embolization

Embolization

Hypervascular TAE

TACE

Hypovascular TARE

Embolotherapy for Cholangiocarcinoma: 2016 Update Summary • Embolotherapy for Cholangiocarcinoma works and improves survival • Low Toxicities • High rate of aggressive futures make embolotherapy a preferable modality for treatment of unresectable cholangiocarcinomas • Mass size correlates with presence of lymphovascular invasion and tumor differentiation • Cholangiocarcinoma enhancement correlates with tumor grade and patients survival • More and better quality research needed.